Summary: Aetna, a CVS Health company, modified CPB 1097 covering etuvetidigene autotemcel (Waskyra) gene therapy, effective May 8, 2026. Here's what billing teams need to know before submitting claims.
This update to the Aetna etuvetidigene autotemcel coverage policy adds structure around one of the newest gene therapies on the market. CPB 1097 Aetna governs Waskyra — a one-time gene therapy approved by the FDA for adenosine deaminase severe combined immunodeficiency (ADA-SCID). The policy does not list specific CPT or HCPCS codes in the available data, so your billing team will need to confirm the correct billing codes directly with Aetna before submitting claims.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Etuvetidigene Autotemcel (Waskyra) — CPB 1097 |
| Policy Code | CPB 1097 |
| Change Type | Modified |
| Effective Date | 2026-05-08 |
| Impact Level | High |
| Specialties Affected | Pediatric Immunology, Hematology/Oncology, Stem Cell Transplant Centers, Specialty Pharmacy |
| Key Action | Verify prior authorization requirements and confirm billing codes with Aetna before submitting any Waskyra claims after May 8, 2026 |
Aetna Etuvetidigene Autotemcel Coverage Criteria and Medical Necessity Requirements 2026
Etuvetidigene autotemcel (Waskyra) is a one-time ex vivo gene therapy. It treats ADA-SCID by inserting a functional ADA gene into the patient's own hematopoietic stem cells. The FDA approved it in 2024, making it one of a small class of approved gene therapies for primary immunodeficiency disorders.
Aetna's coverage policy under CPB 1097 governs whether this treatment meets medical necessity for covered members. Because the available policy data does not include the full criteria text, the specific thresholds Aetna uses to define medical necessity are not fully visible here. That said, based on standard Aetna gene therapy policy patterns and the FDA label for Waskyra, coverage will typically hinge on a confirmed ADA-SCID diagnosis, failure or ineligibility for enzyme replacement therapy (ERT) with pegademase bovine (Adagen), and treatment at a qualified center.
Prior authorization is almost certainly required for this therapy. Gene therapies at this price point — Waskyra carries a list price in the millions — do not move without prior auth. If your facility administers or plans to administer Waskyra, start the prior authorization process well before the infusion date. A single missed step here means a claim denial on a seven-figure charge.
The medical necessity determination will also involve clinical documentation. Expect Aetna to require genetic confirmation of ADA deficiency, documentation of the patient's treatment history, and likely a letter of medical necessity from the treating physician. Get that documentation in order before the effective date of May 8, 2026.
Because this is a modified policy — not a new one — your team should also pull the previous version of CPB 1097 and compare it against the current version. What changed may be as important as what stayed the same. If Aetna tightened the criteria, cases that would have cleared under the old policy may not clear now. If they loosened criteria, there may be newly eligible patients you can now bill for.
Aetna Etuvetidigene Autotemcel Exclusions and Non-Covered Indications
The available policy data does not include the full exclusions list for CPB 1097. However, based on standard Aetna gene therapy coverage policy patterns, expect non-coverage for the following scenarios.
Patients who are candidates for allogeneic hematopoietic stem cell transplantation (HSCT) with a matched sibling donor will likely face a coverage challenge. Aetna typically considers established curative options before approving a gene therapy alternative. Document clearly why HSCT is not appropriate for your patient if that's the clinical picture.
Use outside the FDA-approved indication — ADA-SCID — will almost certainly be excluded. Waskyra billing for other combined immunodeficiency conditions or off-label applications will not meet medical necessity under this coverage policy. Don't submit those claims without a serious conversation with your compliance officer first.
Coverage Indications at a Glance
The full indications list is not available in the current policy data for CPB 1097. The table below reflects what is publicly known about Waskyra's FDA-approved indication and standard Aetna gene therapy coverage patterns. Verify every row against the current policy text before billing.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| ADA-SCID — FDA-approved indication | Expected Covered (with criteria) | Confirm with Aetna | Prior authorization required; medical necessity documentation required |
| ADA-SCID in patients eligible for matched sibling donor HSCT | Likely Not Covered | Confirm with Aetna | HSCT may be considered standard of care first |
| Off-label use (non-ADA-SCID immunodeficiencies) | Not Covered | N/A | Outside FDA-approved indication |
| Retreatment / repeat administration | Likely Not Covered | Confirm with Aetna | One-time gene therapy; retreatment not part of approved use |
Note: This table is based on standard Aetna gene therapy coverage policy patterns and public FDA label information. Confirm all indications against the current CPB 1097 policy text.
Aetna Etuvetidigene Autotemcel Billing Guidelines and Action Items 2026
The financial exposure on a Waskyra claim is unlike almost anything else your billing team handles. Get these steps done before May 8, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the full CPB 1097 policy text from Aetna's provider portal. The policy change was effective May 8, 2026. Read it against the previous version. If you don't have the previous version, contact your Aetna provider relations rep and ask for it. Line-by-line comparison is the only way to know what actually changed. |
| 2 | Confirm the correct HCPCS or CPT billing code for etuvetidigene autotemcel with Aetna directly. The available policy data for CPB 1097 does not list specific codes. Waskyra may bill under a miscellaneous HCPCS code (such as a J-code for unclassified biologics) until a permanent code is assigned. Miscellaneous codes require additional documentation and almost always trigger manual review — plan for a longer reimbursement cycle. |
| 3 | Submit prior authorization requests before scheduling the infusion. Do not schedule a Waskyra administration without confirmed prior auth in hand. Given the list price, Aetna will not pay on a clean claim without it. Build your PA workflow to include genetic test results, diagnosis confirmation, ERT treatment history, and physician attestation of medical necessity. |
| 4 | Coordinate with your specialty pharmacy and infusion center on claim sequencing. Waskyra billing likely involves multiple claim types — professional, facility, and potentially pharmacy. Each one needs to reflect the same authorization number and the same diagnosis codes. A mismatch between claims triggers a claim denial before a human ever reviews the case. |
| 5 | Document the treating center's qualifications. Aetna's gene therapy coverage policies typically require treatment at a center with specific experience and capabilities. Make sure your facility meets any stated requirements and document that clearly in the authorization request and the claim record. |
| 6 | Set up a reimbursement tracking process specific to this therapy. Payment timelines for gene therapies are longer than standard claims. Appeals are more common. Assign someone on your billing team to track every Waskyra claim from auth submission to final payment. Don't let these fall into a standard aging report workflow — they'll disappear. |
| 7 | Talk to your compliance officer before you bill outside the FDA-approved indication. If a physician wants to use Waskyra off-label, that's a compliance conversation, not a billing one. The coverage policy will not support it, and the financial and legal exposure is real. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Etuvetidigene Autotemcel Under CPB 1097
The current policy data for CPB 1097 Aetna does not include specific CPT, HCPCS, or ICD-10 codes. This is common for newly approved gene therapies — permanent J-codes are often assigned 12–18 months after FDA approval, and Waskyra's 2024 approval timeline means a permanent code may be in process.
What to Do Instead of Guessing
Contact Aetna's provider services line and ask specifically which HCPCS code to use for etuvetidigene autotemcel billing. Ask whether Aetna has issued a billing bulletin or coding guidance for Waskyra. Some payers assign internal codes or require specific unlisted/miscellaneous HCPCS codes during the period before a permanent code is issued.
For diagnosis coding, the expected primary diagnosis is ADA-SCID. The likely ICD-10-CM code is D81.31 (Adenosine deaminase [ADA] deficiency). Confirm this against Aetna's current CPB 1097 policy text — the policy may specify additional or alternative diagnosis codes required for prior authorization and claim submission.
Do not use this section as a substitute for confirmed billing guidelines from Aetna. The stakes on a miscoded gene therapy claim are too high to rely on assumed codes.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.